POU2F3 and neoplasm: In particular, we confirmed that KIT‐targeting drugs, such as pazopanib, are potentially adequate to target POU2F3‐driven SCLCs, whereas YAP1‐driven tumours are more resistant to vorinostat (targeting HDAC1).